4/A: AVNS SVP Corrects Stock Option Grant Details

AVANOS Medical's SVP of Operations, Sigfrido Delgado, filed an amended Form 4 to correct an error in a previously reported stock option grant.

Summary

• Sigfrido Delgado, SVP of Operations at AVANOS Medical, Inc. (AVNS), filed a Form 4/A to amend a previous filing regarding beneficial ownership.
• The amendment corrects an erroneous addition to the number of stock options issued to Mr. Delgado on March 13, 2026.
• The original Form 4 filed on March 17, 2026, correctly reported the number of stock options.
• On March 13, 2026, Mr. Delgado acquired 15,886 time-based restricted share units (TRSUs) at a price of $0, bringing his total direct beneficial ownership of common stock to 60,005 shares.
• These TRSUs will vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029, under the Issuer's 2021 Long Term Incentive Plan.
• Also on March 13, 2026, Mr. Delgado acquired 37,520 employee stock options with an exercise price of $13.69, resulting in 59,434 derivative securities beneficially owned directly.
• These stock options will vest 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029, and expire on March 13, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It primarily concerns a routine executive compensation disclosure and an administrative correction, neither of which significantly alters the company's fundamental outlook or operational status.

Positives

• The grant of 15,886 time-based restricted share units (TRSUs) and 37,520 employee stock options aligns the interests of the SVP of Operations with those of shareholders.
• The vesting schedule for both TRSUs and stock options encourages long-term commitment and performance from a key executive.

Negatives

• The need for an amendment (Form 4/A) indicates an administrative error in a previous filing, though it appears to be a correction of an overstatement of options.

Future Outlook

The filing details future vesting schedules for executive equity awards, indicating a planned long-term incentive structure for the SVP of Operations through March 2029.

Management Comments

• The Form 4/A is being filed to correct a Form 4/A filed on April 1, 2026, that erroneously added to the number of stock options issued to the Reporting Person on March 13, 2026, pursuant to the Issuer's 2021 Long-Term Incentive Plan, as amended.
• The number of stock options originally reported in the Form 4 filed on March 17, 2026, was correct.

Industry Context

StockSavvy.ai notes that executive equity compensation, including restricted stock units and stock options, is a standard practice across the medical device and healthcare industry. These awards are designed to align executive incentives with shareholder value creation and long-term company performance. The correction of an administrative error in a filing is also a routine occurrence in SEC reporting.

Comparison to Industry Standards

• The use of time-based restricted share units and employee stock options as part of executive compensation is consistent with common practices among publicly traded companies in the medical technology sector, such as Medtronic (MDT) or Stryker (SYK), which frequently utilize similar long-term incentive plans to retain talent and motivate performance.
• The vesting schedule, spanning three years, is typical for such awards, promoting sustained executive engagement rather than short-term gains.

Stakeholder Impact

• Shareholders: The equity awards align executive interests with shareholder value, potentially fostering long-term growth. The correction ensures accurate public record of insider holdings.
• Employees: No direct impact on the broader employee base, but reflects the company's executive compensation strategy.
• Management: The SVP of Operations receives significant equity incentives, tying a portion of their wealth to the company's stock performance.

Next Steps

• The awarded TRSUs will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028, and 1/3 on March 13, 2029.
• The awarded stock options will vest 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029.

Key Dates

Keywords

AVANOS Medical, AVNS, Form 4/A, SEC filing, insider trading, stock options, restricted share units, executive compensation, beneficial ownership, long-term incentive plan